Skip to main content

Biomedical Research in Melanoma

The Biomedical Research in Melanoma group is interested in skin cancer. We investigate the molecular causes for these diseases to design effective therapies against them. Our research is done in close proximity to patients, where our goal is to translate our discoveries as fast as possible to the clinic. To that end, we have a multidisciplinary group that associate dermatologists, oncologists, pathologists and basic-scientists that ask relevant clinical questions that need biological answers.

Our workflow contemplates information obtained from patients (genetic information, clinical history, functional data…) that is translated into animal models (genetic modified mouse models, PDX…) and in vitro experiments to answer the formulated questions. These results are used to design novel therapeutic approaches, including drug development and preclinical studies that ultimately will be translated to patients. 

The main lines of investigation are: 
•    Molecular mechanisms involved in melanoma development and progression, 
•    Targeting metabolism for melanoma treatment,
•    The mechanisms of resistance to immunotherapy.
 

Team

Gabriela Gomez Andrade

Gabriela Gomez Andrade

Research technician
Biomedical Research in Melanoma
Read more
Berta Ferrer Fábrega

Berta Ferrer Fábrega

Biomedical Research in Melanoma
Read more
Carlos  González Cruz

Carlos González Cruz

Predoctoral researcher
Biomedical Research in Melanoma
Read more
Juan Angel Recio Conde

Juan Angel Recio Conde

Head of group
Biomedical Research in Melanoma
Read more
Kimberley Anne McGrail Fernández

Kimberley Anne McGrail Fernández

Predoctoral researcher
Biomedical Research in Melanoma
Read more
Pablo Marino Castro Garcia

Pablo Marino Castro Garcia

Read more
Gabriela Gomez Andrade

Gabriela Gomez Andrade

Research technician
Biomedical Research in Melanoma
Read more
Berta Ferrer Fábrega

Berta Ferrer Fábrega

Biomedical Research in Melanoma
Read more
Carlos  González Cruz

Carlos González Cruz

Predoctoral researcher
Biomedical Research in Melanoma
Read more
Juan Angel Recio Conde

Juan Angel Recio Conde

Head of group
Biomedical Research in Melanoma
Read more
Kimberley Anne McGrail Fernández

Kimberley Anne McGrail Fernández

Predoctoral researcher
Biomedical Research in Melanoma
Read more
Pablo Marino Castro Garcia

Pablo Marino Castro Garcia

Read more

Research lines

Deciphering oncogene-driven metabolism settings in malignant melanoma with therapeutic purposes

Metabolic settings of aggressive tumor cells adapt to their energetic and anabolic demands. While limited success in cancer treatment using targeted therapy has been accomplished, the altered metabolism of tumor cells compared to normal cells, provides a viable novel target for a non-toxic chemotherapeutic approach. Since tumor cells can utilize different metabolic strategies that have only now being elucidated, deciphering which metabolic settings are associated to a particular mutational status would be helpful to both design novel therapeutic strategies and stratify patients for treatment. In melanoma ~50% of tumors present activating mutations in BRAF (BRAFV600E) and another 20% present activating mutations in NRAS (NRASQ61L). While targeted therapy of BRAFV600E mutant tumors has been partially successful there is no therapeutic alternative for patients harboring NRASQ61L mutant tumors. Despite the fact that these molecules affect the same pathway (RAS-ERK1/2), BRAFV600E and NRASQ61L mutant cells behave and respond differently to therapy and to metabolic stress. Understanding the metabolic settings of BRAFV600E and NRASQ61L mutant melanoma tumors would help to sensitize them, overcome resistance mechanisms to therapy and target them according to their genetic alterations. This project is been supported by Marie Curie actions. Expected results: After execution of this project the main expected results are: 1. To define the different metabolic settings of melanomas harboring diferent oncogenic mutations 2. To identify the biochemical mechanism responsible for the differential metabolic stress response acconding to their genotype 3. To design of novel therapeutic alternatives to treat melanoma tumors.

IP: -

Novel therapeutic strategies for melanoma treatment

IP: -

Preclinical study in lung and melanoma using ALDH specific inhibitors

To translate our reseach into the clinic is one of our main objetives. We are currently conducting a preclinical study in colaboration with the Industry to test the therapeutic capabilities of ALDH isoform-specific inhibidors in melanoma, lung and breast tumors. The aims of this project are: To identify the ALDH isoforms and the metabolic settings associated to oncògenes To verify a cause and effect relationship between the increased activity of a specific ALDH isoform and the resistance to cell death manifest. To identify which of the endogenous substrates of ALDH and corresponding reaction products are specifically involved in cell death resistance. To evaluate the therapeutic efficacy of specific inhibitors of ALDHs

IP: -

Role of LKB1 in tumor biology: LKB1 role in UVB-induced DNA damage response

Environmental insults are directly involved in cancer development. In particular, Ultraviolet (UV) radiation has been associated to the acquisition of different types of skin cancer and premature skin aging. UV radiation causes modifications in the genetic material of cells (DNA) that if not repaired properly will lead to a mutated DNA (mutated genes) which might trigger the development of cancer. Understanding the molecular basis of the UV-induced DNA damage response is important to elucidate the mechanisms of skin tumorigenesis. In the study, published in Plos Genetics, the authors used a UV-induced skin cancer mouse model (Hepatocyte growth factor (HGF) transgenic mice), where one of the two Lkb1 gene alleles was deleted (haploinsufficiency), and consequently the amounts of LKB1 protein was half of the normal levels. A single dose of UVB radiation in Lkb1 haploinsufficient neonates mice expressing HGF was enough to induced the quickly development of squamous cell carcinomas, and this, was associated to a deficient response in DNA damage repair. Moreover, cells harboring the damaged DNA were resistant to cell death (apoptosis). Thus, lack of LKB1 promotes a double effect: cells not only fail to repair the damage in their DNA, but they do not die, leading to the accumulation of mutated cells and the development of tumors. The research team has obtained similar results (to be published soon) in two additional mouse models of melanoma, a much more lethal type of UV-induced skin cancer. One of the beauties of this model is that reflects the real scenario for cancer adquisition where initially just one of gene copies is damaged. It also reproduces a tumor related to chronic DNA damage using a single dose of UV radiation, underlining the importance of this protein’s function. LKB1 mutations have been found epithelial human cancers associated to environmental insults. “However, this is the first study that links LKB1 to the UV-induced DNA repair responses” explains Dr. Recio, “and provides an important insight into how cells can defend themselves from external genotoxic damage”. Importantly, these results can be extrapolated to human cancer. In fact, when examining the expression of LKB1 protein in samples from patients with skin tumors, the authors found that roughly half of these samples showed low or no expression of LKB1. Furthermore, absence of the protein was detected in all stages of the disease, particularly in UV-exposed skin areas, suggesting that the loss of expression of LKB1 is an early event and very likely contributes to UV-induced skin cancer development. In the near future, we will be evaluating LKB1 as a prognostic risk factor for UV–induced skin cancer. They also are investigating the different factors that may alter LKB1 expression, with a particular emphasis in families with skin cancer predisposition or skin cancer history.

IP: -

Projects

Papel de p38a en melanoma

IP: Juan Angel Recio Conde
Collaborators: Paula Granado Martinez, Judit Álvarez González
Funding agency: AGAUR
Funding: 63589.78
Reference: 2021 FI_B 00017
Duration: 01/04/2021 - 31/03/2024

p38a in control of UV-induced melanoma development

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundación Ramón Areces
Funding: 129371
Reference: ARECES/XIX/CIENCIES.VIDA/RECIO
Duration: 03/04/2019 - 02/04/2022

Oncogene-mediated intratumoral immune-cell populations at different organs as biomarkers of immunotherapy response

IP: Juan Angel Recio Conde
Collaborators: Paula Granado Martinez, Kimberley Anne McGrail Fernández, Vicente García-Patos Briones, Berta Ferrer Fábrega, Oncogene-mediated intratumoral immune-cell populations at different organs as biomarkers of immunotherapy response
Funding agency: Instituto de Salud Carlos III
Funding: 341220
Reference: PI20/00384
Duration: 01/01/2021 - 31/12/2023

Papel de p38a en melanoma

IP: Juan Angel Recio Conde
Collaborators: Paula Granado Martinez, Judit Álvarez González
Funding agency: AGAUR
Funding: 63589.78
Reference: 2021 FI_B 00017
Duration: 01/04/2021 - 31/03/2024

Estudio de la cooperación de la vía de estrés (MAPK14) en el desarrollo, progresión y regulación de la respuesta inmune intra-tumoral en melanoma con fines terapéuticos

IP: Juan Angel Recio Conde
Collaborators: Kimberley Anne McGrail Fernández, Vicente García-Patos Briones, Estudio de la cooperación de la vía de estrés (MAPK14) en el desarrollo, progresión y regulación de la respuesta inmune intra-tu
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI17/00043
Duration: 01/01/2018 - 30/06/2021

p38a in control of UV-induced melanoma development

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundación Ramón Areces
Funding: 129371
Reference: ARECES/XIX/CIENCIES.VIDA/RECIO
Duration: 03/04/2019 - 02/04/2022

Oncogene-mediated intratumoral immune-cell populations at different organs as biomarkers of immunotherapy response

IP: Juan Angel Recio Conde
Collaborators: Paula Granado Martinez, Kimberley Anne McGrail Fernández, Vicente García-Patos Briones, Berta Ferrer Fábrega, Oncogene-mediated intratumoral immune-cell populations at different organs as biomarkers of immunotherapy response
Funding agency: Instituto de Salud Carlos III
Funding: 341220
Reference: PI20/00384
Duration: 01/01/2021 - 31/12/2023

Vías de diseminación metastásica en distintos subtipos del melanoma maligno: Nuevos biomarcadores tumorales y dianas terapéuticas.

IP: Juan Angel Recio Conde
Collaborators: Vicente García-Patos Briones, Berta Ferrer Fábrega
Funding agency: Asociación Española Contra el Cáncer
Funding: 212500
Reference: 2015/AECC-GCE/RECIO
Duration: 01/07/2015 - 31/12/2020

Estudio de la cooperación de la vía de estrés (MAPK14) en el desarrollo, progresión y regulación de la respuesta inmune intra-tumoral en melanoma con fines terapéuticos

IP: Juan Angel Recio Conde
Collaborators: Kimberley Anne McGrail Fernández, Vicente García-Patos Briones, Estudio de la cooperación de la vía de estrés (MAPK14) en el desarrollo, progresión y regulación de la respuesta inmune intra-tu
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI17/00043
Duration: 01/01/2018 - 30/06/2021

p38a in control of UV-induced melanoma development

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundación Ramón Areces
Funding: 129371
Reference: ARECES/XIX/CIENCIES.VIDA/RECIO
Duration: 03/04/2019 - 02/04/2022

S

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding:
Reference: SENIORITY/2016/RECIO
Duration: 03/01/2017 - 02/01/2019

Vías de diseminación metastásica en distintos subtipos del melanoma maligno: Nuevos biomarcadores tumorales y dianas terapéuticas.

IP: Juan Angel Recio Conde
Collaborators: Vicente García-Patos Briones, Berta Ferrer Fábrega
Funding agency: Asociación Española Contra el Cáncer
Funding: 212500
Reference: 2015/AECC-GCE/RECIO
Duration: 01/07/2015 - 31/12/2020

Modulation of melanoma-stroma interactions using a rationally-designed nanomedicine combining BRAFi-, MEKi- and immunetherapies

IP: Juan Angel Recio Conde
Collaborators: Berta Ferrer Fábrega, Modulation of melanoma-stroma interactions using a rationally-designed nanomedicine combining BRAFi-, MEKi- and immunetherapies
Funding agency: Instituto de Salud Carlos III
Funding: 96072.79
Reference: AC16/00019
Duration: 01/01/2017 - 31/12/2019

Estudio de la cooperación de la vía de estrés (MAPK14) en el desarrollo, progresión y regulación de la respuesta inmune intra-tumoral en melanoma con fines terapéuticos

IP: Juan Angel Recio Conde
Collaborators: Kimberley Anne McGrail Fernández, Vicente García-Patos Briones, Estudio de la cooperación de la vía de estrés (MAPK14) en el desarrollo, progresión y regulación de la respuesta inmune intra-tu
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI17/00043
Duration: 01/01/2018 - 30/06/2021

S

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding:
Reference: SENIORITY/2016/RECIO
Duration: 03/01/2017 - 02/01/2019

Estudio de las configuraciones metabólicas inducidas por oncogenes en melanoma maligno con fines terapéuticos

IP: Juan Angel Recio Conde
Collaborators: Berta Ferrer Fábrega, Estudio de las configuraciones metabólicas inducidas por oncogenes en melanoma maligno con fines terapéuticos
Funding agency: Instituto de Salud Carlos III
Funding: 207515
Reference: PI14/00475
Duration: 01/01/2015 - 30/06/2018

Vías de diseminación metastásica en distintos subtipos del melanoma maligno: Nuevos biomarcadores tumorales y dianas terapéuticas.

IP: Juan Angel Recio Conde
Collaborators: Vicente García-Patos Briones, Berta Ferrer Fábrega
Funding agency: Asociación Española Contra el Cáncer
Funding: 212500
Reference: 2015/AECC-GCE/RECIO
Duration: 01/07/2015 - 31/12/2020

Modulation of melanoma-stroma interactions using a rationally-designed nanomedicine combining BRAFi-, MEKi- and immunetherapies

IP: Juan Angel Recio Conde
Collaborators: Berta Ferrer Fábrega, Modulation of melanoma-stroma interactions using a rationally-designed nanomedicine combining BRAFi-, MEKi- and immunetherapies
Funding agency: Instituto de Salud Carlos III
Funding: 96072.79
Reference: AC16/00019
Duration: 01/01/2017 - 31/12/2019

Estudio de la función de LKB1 y de los mutantes asociados a melanoma dirigido a la creación de terapias personalizadas efectivas

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 45135
Reference: PRED-VHIR-2013-16
Duration: 12/12/2014 - 11/12/2017

S

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding:
Reference: SENIORITY/2016/RECIO
Duration: 03/01/2017 - 02/01/2019

Pathways of proliferation and survival in chemotherapy-refractory cancer stem cells.

IP: -
Collaborators: -
Funding agency: Fundació La Marató de TV3
Funding: 165000
Reference: 20132530
Duration: 14/03/2014 - 13/03/2017

Estudio de las configuraciones metabólicas inducidas por oncogenes en melanoma maligno con fines terapéuticos

IP: Juan Angel Recio Conde
Collaborators: Berta Ferrer Fábrega, Estudio de las configuraciones metabólicas inducidas por oncogenes en melanoma maligno con fines terapéuticos
Funding agency: Instituto de Salud Carlos III
Funding: 207515
Reference: PI14/00475
Duration: 01/01/2015 - 30/06/2018

Unraveling metabolic settings and targeting metabolic enzymes with selective lethality in BRAF and NRAS mutant melanoma tumors (METABOSET) Grant agreement nº 627869

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 173370.6
Reference: METABOSET_FP7PEOPLE-IEF2013
Duration: 01/04/2014 - 31/03/2016

Estudio de la función de LKB1 y de los mutantes asociados a melanoma dirigido a la creación de terapias personalizadas efectivas

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 45135
Reference: PRED-VHIR-2013-16
Duration: 12/12/2014 - 11/12/2017

Pathways of proliferation and survival in chemotherapy-refractory cancer stem cells.

IP: -
Collaborators: -
Funding agency: Fundació La Marató de TV3
Funding: 165000
Reference: 20132530
Duration: 14/03/2014 - 13/03/2017

Estudio de las configuraciones metabólicas inducidas por oncogenes en melanoma maligno con fines terapéuticos

IP: Juan Angel Recio Conde
Collaborators: Berta Ferrer Fábrega, Estudio de las configuraciones metabólicas inducidas por oncogenes en melanoma maligno con fines terapéuticos
Funding agency: Instituto de Salud Carlos III
Funding: 207515
Reference: PI14/00475
Duration: 01/01/2015 - 30/06/2018

Unraveling metabolic settings and targeting metabolic enzymes with selective lethality in BRAF and NRAS mutant melanoma tumors (METABOSET) Grant agreement nº 627869

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 173370.6
Reference: METABOSET_FP7PEOPLE-IEF2013
Duration: 01/04/2014 - 31/03/2016

Estudio de la función de LKB1 y de los mutantes asociados a melanoma dirigido a la creación de terapias personalizadas efectivas

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 45135
Reference: PRED-VHIR-2013-16
Duration: 12/12/2014 - 11/12/2017

Estudio de la función de LKB1 y de los mutantes asociados a melanoma dirigido a la creación de terapias personalizadas efectivas

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 167541.44
Reference: PI11/00384
Duration: 01/01/2012 - 28/02/2015

Pathways of proliferation and survival in chemotherapy-refractory cancer stem cells.

IP: -
Collaborators: -
Funding agency: Fundació La Marató de TV3
Funding: 165000
Reference: 20132530
Duration: 14/03/2014 - 13/03/2017

Unraveling metabolic settings and targeting metabolic enzymes with selective lethality in BRAF and NRAS mutant melanoma tumors (METABOSET) Grant agreement nº 627869

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 173370.6
Reference: METABOSET_FP7PEOPLE-IEF2013
Duration: 01/04/2014 - 31/03/2016

Estudio de la función de LKB1 y de los mutantes asociados a melanoma dirigido a la creación de terapias personalizadas efectivas

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 45135
Reference: PRED-VHIR-2013-16
Duration: 12/12/2014 - 11/12/2017

Estudio de la función de LKB1 y de los mutantes asociados a melanoma dirigido a la creación de terapias personalizadas efectivas

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 167541.44
Reference: PI11/00384
Duration: 01/01/2012 - 28/02/2015

Pathways of proliferation and survival in chemotherapy-refractory cancer stem cells.

IP: -
Collaborators: -
Funding agency: Fundació La Marató de TV3
Funding: 165000
Reference: 20132530
Duration: 14/03/2014 - 13/03/2017

Estudio de la función de LKB1 y de los mutantes asociados a melanoma dirigido a la creación de terapias personalizadas efectivas

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 167541.44
Reference: PI11/00384
Duration: 01/01/2012 - 28/02/2015

Role of methylation in MAPK signal transduction pathways.

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: AGAUR
Funding: 60147.96
Reference: 2011FI_B2 00205
Duration: 30/01/2009 - 29/01/2012

Papel de LKB1 en respuesta a factores de crecimiento y en el desarrollo y progresión del melanoma

IP: Juan Angel Recio Conde
Collaborators: Anna Pujol Esclusa
Funding agency: Instituto de Salud Carlos III
Funding: 225907
Reference: PI080653
Duration: 01/01/2009 - 31/03/2012

Estudio de la función de LKB1 y de los mutantes asociados a melanoma dirigido a la creación de terapias personalizadas efectivas

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 167541.44
Reference: PI11/00384
Duration: 01/01/2012 - 28/02/2015

Role of methylation in MAPK signal transduction pathways.

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: AGAUR
Funding: 60147.96
Reference: 2011FI_B2 00205
Duration: 30/01/2009 - 29/01/2012

Papel de LKB1 en respuesta a factores de crecimiento y en el desarrollo y progresión del melanoma

IP: Juan Angel Recio Conde
Collaborators: Anna Pujol Esclusa
Funding agency: Instituto de Salud Carlos III
Funding: 225907
Reference: PI080653
Duration: 01/01/2009 - 31/03/2012

Role of methylation in MAPK signal transduction pathways.

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: AGAUR
Funding: 60147.96
Reference: 2011FI_B2 00205
Duration: 30/01/2009 - 29/01/2012

Papel de LKB1 en melanoma maligno

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundación Invest. Médica Mutua Madrileña
Funding: 61000
Reference: FMMA/12/2006
Duration: 18/04/2007 - 17/04/2010

Papel de LKB1 en respuesta a factores de crecimiento y en el desarrollo y progresión del melanoma

IP: Juan Angel Recio Conde
Collaborators: Anna Pujol Esclusa
Funding agency: Instituto de Salud Carlos III
Funding: 225907
Reference: PI080653
Duration: 01/01/2009 - 31/03/2012

Characterization of novel acting mechanisms of the Hepatocyte Growth Factor (HGF) in melonomagenesis: Bring into play the HGF transgenic animal model

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13622
Reference: PRED/IR-HUVH/17/2005
Duration: 01/01/2006 - 31/12/2009

Pleclinical study of PI3k and Braf inhibidors in melanoma

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: AGAUR
Funding: 955
Reference: 2006FI 00739
Duration: 01/01/2006 - 31/12/2009

Role of methylation in MAPK signal transduction pathways.

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: AGAUR
Funding: 60147.96
Reference: 2011FI_B2 00205
Duration: 30/01/2009 - 29/01/2012

Mecanismos de actuación del Factor de Crecimiento Hepático (HGF) en la adquisición y progresión del melanoma cutáneo: aplicación del modelo animal de melanoma maligno basado en ratones transgénicos del HGF

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 171360
Reference: PI050227
Duration: 01/01/2006 - 30/09/2009

Characterization of novel acting mechanisms of the Hepatocyte Growth Factor (HGF) in melonomagenesis: Bring into play the HGF transgenic animal model

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13622
Reference: PRED/IR-HUVH/17/2005
Duration: 01/01/2006 - 31/12/2009

Pleclinical study of PI3k and Braf inhibidors in melanoma

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: AGAUR
Funding: 955
Reference: 2006FI 00739
Duration: 01/01/2006 - 31/12/2009

Mecanismos de actuación del Factor de Crecimiento Hepático (HGF) en la adquisición y progresión del melanoma cutáneo: aplicación del modelo animal de melanoma maligno basado en ratones transgénicos del HGF

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 171360
Reference: PI050227
Duration: 01/01/2006 - 30/09/2009

Characterization of novel acting mechanisms of the Hepatocyte Growth Factor (HGF) in melanomagenesis: Bring into play the HGF transgenic animal model (Mouse melanoma model) Contract No 029135 MIRG-CT-2005-029135 Marie Curie International Reintegra

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 80000
Reference: MIRG-CT-2005-029135
Duration: 01/01/2006 - 01/04/2008

Characterization of novel acting mechanisms of the Hepatocyte Growth Factor (HGF) in melonomagenesis: Bring into play the HGF transgenic animal model

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13622
Reference: PRED/IR-HUVH/17/2005
Duration: 01/01/2006 - 31/12/2009

Pleclinical study of PI3k and Braf inhibidors in melanoma

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: AGAUR
Funding: 955
Reference: 2006FI 00739
Duration: 01/01/2006 - 31/12/2009

Mecanismos de actuación del Factor de Crecimiento Hepático (HGF) en la adquisición y progresión del melanoma cutáneo: aplicación del modelo animal de melanoma maligno basado en ratones transgénicos del HGF

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 171360
Reference: PI050227
Duration: 01/01/2006 - 30/09/2009

Characterization of novel acting mechanisms of the Hepatocyte Growth Factor (HGF) in melanomagenesis: Bring into play the HGF transgenic animal model (Mouse melanoma model) Contract No 029135 MIRG-CT-2005-029135 Marie Curie International Reintegra

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 80000
Reference: MIRG-CT-2005-029135
Duration: 01/01/2006 - 01/04/2008

Characterization of novel acting mechanisms of the Hepatocyte Growth Factor (HGF) in melonomagenesis: Bring into play the HGF transgenic animal model

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13622
Reference: PRED/IR-HUVH/17/2005
Duration: 01/01/2006 - 31/12/2009

Pleclinical study of PI3k and Braf inhibidors in melanoma

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: AGAUR
Funding: 955
Reference: 2006FI 00739
Duration: 01/01/2006 - 31/12/2009

Mecanismos de actuación del Factor de Crecimiento Hepático (HGF) en la adquisición y progresión del melanoma cutáneo: aplicación del modelo animal de melanoma maligno basado en ratones transgénicos del HGF

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 171360
Reference: PI050227
Duration: 01/01/2006 - 30/09/2009

Characterization of novel acting mechanisms of the Hepatocyte Growth Factor (HGF) in melanomagenesis: Bring into play the HGF transgenic animal model (Mouse melanoma model) Contract No 029135 MIRG-CT-2005-029135 Marie Curie International Reintegra

IP: Juan Angel Recio Conde
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 80000
Reference: MIRG-CT-2005-029135
Duration: 01/01/2006 - 01/04/2008

Publications

Prurigiform angiomatosis: report of three cases and review of the literature.

PMID: 35781803
Journal: INTERNATIONAL JOURNAL OF DERMATOLOGY
Year: 2022
Reference: Int J Dermatol. 2022 Jul 3. doi: 10.1111/ijd.16345.
Impact factor: 2.736
Publication type: Letter or abstract
Authors: Fernandez-Figueras, Maria-Teresa; Garcia-Patos Briones, Vicente; Perez-Munoz, Noelia; Barrabes-Torrella, Cristina; Salleras-Redonnet, Montse; Quintana-Codina, Monica; Gonzalez-Cruz, Carlos et al.
DOI: 10.1111/ijd.16345

Effects of COVID-19 Lockdown on Tumour Burden of Melanoma and Cutaneous Squamous Cell Carcinoma.

PMID: 34396424
Journal: ACTA DERMATO-VENEREOLOGICA
Year: 2021
Reference: Acta Derm Venereol. 2021 Aug 25;101(8):adv00525. doi: 10.2340/00015555-3890.
Impact factor: 4.437
Publication type: Paper in international publication
Authors: Tejera-Vaquerizo, Antonio, Paradela, Sabela, Toll, Agusti, Santos-Juanes, Jorge, Jaka, Ane, Taberner, Rosa, Rodenas-Herranz, Teresa, Garcia-Donoso, Carmen, Puig, Susana, Nagore, Eduardo et al.
DOI: 10.2340/00015555-3890

Posttransplant Kaposi sarcoma: Analysis of a series of 13 patients.

PMID: 34246484
Journal: MEDICINA CLINICA
Year: 2021
Reference: Med Clin (Barc). 2021 Oct 8;157(7):339-343. doi: 10.1016/j.medcli.2021.04.030. Epub 2021 Jul 7.
Impact factor: 1.725
Publication type: Letter or abstract
Authors: Ferrer Fabregas, Berta, Gonzalez-Cruz, Carlos, Ferrandiz-Pulido, Carla, Garcia-Patos Briones, Vicente et al.
DOI: 10.1016/j.medcli.2021.04.030

Melanoma in Solid Organ Transplant Recipients.

PMID: 33197437
Journal: Actas dermo-sifiliograficas
Year: 2021
Reference: Actas Dermosifiliogr. 2021 Mar;112(3):216-224. doi: 10.1016/j.ad.2020.11.005. Epub 2020 Nov 13.
Impact factor: 0
Publication type: Review in national publication
Authors: Gonzalez-Cruz, C, Ferrandiz-Pulido, C, Garcia-Patos Briones, V et al.
DOI: 10.1016/j.ad.2020.11.005

Mediastinal FDG-positive lymph nodes simulating melanoma progression: drug-induced sarcoidosis like/lymphadenopathy related to ipilimumab.

PMID: 33509865
Journal: BMJ case reports
Year: 2021
Reference: BMJ Case Rep. 2021 Jan 28;14(1). pii: 14/1/e237310. doi: 10.1136/bcr-2020-237310.
Impact factor: 0
Publication type: Letter or abstract
Authors: Gonzalez-Cruz, Carlos, Bodet, Domingo, Munoz-Couselo, Eva, Garcia-Patos, Vicente et al.
DOI: 10.1136/bcr-2020-237310

Leucocytoclastic vasculitis in a patient with COVID-19 with positive SARS-CoV-2 PCR in skin biopsy.

PMID: 33122236
Journal: BMJ case reports
Year: 2020
Reference: BMJ Case Rep. 2020 Oct 29;13(10). pii: 13/10/e238039. doi: 10.1136/bcr-2020-238039.
Impact factor: 0
Publication type: Paper in international publication
Authors: Camprodon Gomez, Maria, Gonzalez-Cruz, Carlos, Ferrer, Berta, Barbera, Maria Jesus et al.
DOI: 10.1136/bcr-2020-238039

Maculopapular eruptions associated to COVID-19: a subanalysis of the COVID-Piel study.

PMID: 32779280
Journal: Dermatologic Therapy
Year: 2020
Reference: Dermatol Ther. 2020 Nov;33(6):e14170. doi: 10.1111/dth.14170. Epub 2020 Sep 9.
Impact factor: 2.327
Publication type: Paper in international publication
Authors: Llamas-Velasco, Mar, Carnero-Gonzalez, Lucia, Garcia-Gavin, Juan, Baniandres, Ofelia, Gonzalez-Cruz, Carlos, Morillas-Lahuerta, Victor, Cubiro, Xavier, Figueras, Ignasi, Selda-Enriquez, Gerald, Fusta-Novell, Xavier et al.
DOI: 10.1111/dth.14170

STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation.

PMID: 32647375
Journal: Communications Biology
Year: 2020
Reference: Commun Biol. 2020 Jul 9;3(1):366. doi: 10.1038/s42003-020-1092-0.
Impact factor: 4.165
Publication type: Paper in international publication
Authors: Granado-Martinez, Paula, Garcia-Ortega, Sara, Gonzalez-Sanchez, Elena, McGrail, Kimberley, Selgas, Rafael, Grueso, Judit, Gil, Rosa, Naldaiz-Gastesi, Neia, Rhodes, Ana C, Hernandez-Losa, Javier et al.
DOI: 10.1038/s42003-020-1092-0

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.

PMID: 32348545
Journal: BRITISH JOURNAL OF DERMATOLOGY
Year: 2020
Reference: Br J Dermatol. 2020 Jul;183(1):71-77. doi: 10.1111/bjd.19163. Epub 2020 Jun 10.
Impact factor: 7
Publication type: Paper in international publication
Authors: Galvan Casas, C, Catala, A, Carretero Hernandez, G, Rodriguez-Jimenez, P, Fernandez Nieto, D, Rodriguez-Villa Lario, A, Navarro Fernandez, I, Ruiz-Villaverde, R, Falkenhain, D, Llamas Velasco, M et al.
DOI: 10.1111/bjd.19163

Proportion of Potentially Avoidable Referrals From Primary Care to Dermatologists for Cystic Lesions or Benign Neoplasms in Spain: Analysis of Data from the DIADERM Study.

PMID: 31153547
Journal: Actas dermo-sifiliograficas
Year: 2019
Reference: Actas Dermosifiliogr. 2019 Oct;110(8):659-665. doi: 10.1016/j.ad.2019.02.003. Epub 2019 May 29.
Impact factor: 0
Publication type: Paper in national publication
Authors: Gonzalez-Cruz, C, Descalzo, M A, Arias-Santiago, S, Molina-Leyva, A, Gilaberte, Y, Fernandez-Crehuet, P, Viera-Ramirez, A, Fernandez-Penas, P, Taberner, R, Buendia-Eisman, A et al.
DOI: 10.1016/j.ad.2019.02.003

Indurated Papules on the Face.

PMID: 30850121
Journal: Actas dermo-sifiliograficas
Year: 2019
Reference: Actas Dermosifiliogr. 2019 Sep;110(7):599-600. doi: 10.1016/j.ad.2018.01.018. Epub 2019 Mar 6.
Impact factor: 0
Publication type: Paper in national publication
Authors: Gonzalez-Cruz, C, Cabezas Calderon, V, Garcia-Patos Briones, V et al.
DOI: 10.1016/j.ad.2018.01.018

Cutaneous infections by dematiaceous opportunistic fungi: diagnosis and management in 11 solid organ transplant recipients.

PMID: 30230044
Journal: MYCOSES
Year: 2019
Reference: Mycoses. 2019 Feb;62(2):121-127. doi: 10.1111/myc.12853. Epub 2018 Oct 17.
Impact factor: 3.065
Publication type: Paper in international publication
Authors: Ferrandiz-Pulido, C, Martin-Gomez, M T, Repiso, T, Juarez, C, Ferrer, B, Lopez-Lerma, I, Gonzalez-Cruz, C, Moreso, F, Roman, A, Garcia-Patos, V et al.
DOI: 10.1111/myc.12853

Lupus panniculitis: Clinicopathological features of a series of 12 patients.

PMID: 30154008
Journal: MEDICINA CLINICA
Year: 2018
Reference: Med Clin (Barc). 2018 Dec 14;151(11):444-449. doi: 10.1016/j.medcli.2018.06.024. Epub 2018 Aug 25.
Impact factor: 1.168
Publication type: Paper in national publication
Authors: Gonzalez-Cruz, Carlos, Aparicio Espanol, Gloria, Ferrer Fabrega, Berta, Cabezas Calderon, Victor, Giner Pichel, Mario, Garcia-Patos Briones, Vicente et al.
DOI: 10.1016/j.medcli.2018.06.024

Genetic Profiles of Squamous Cell Carcinomas Associated with Recessive Dystrophic Epidermolysis Bullosa Unveil NOTCH and TP53 Mutations and an Increased MYC Expression.

PMID: 29291383
Journal: JOURNAL OF INVESTIGATIVE DERMATOLOGY
Year: 2018
Reference: J Invest Dermatol. 2018 Jun;138(6):1423-1427. doi: 10.1016/j.jid.2017.12.026. Epub 2017 Dec 29.
Impact factor: 6.448
Publication type: Paper in international publication
Authors: Vivancos, A, Garcia-Patos, V, Recio, J A, Bodet, D, Hernandez-Losa, J, Perez-Alea, M, Sans-DeSanNicolas, L, Caratu, G, Vidal-Cortes, O, Sanchez-Redondo, S et al.
DOI: 10.1016/j.jid.2017.12.026

Thesis

Targeting NRAS mutant melanomas through metabolic stress.

PhD student: Kimberley Anne McGrail Fernández
Director/s: Juan Angel Recio Conde
University: Universitat Autònoma de Barcelona
Year: 2021

Study of the in vivo cooperation between oncogenic BRAF, LKB1 loss and UV irradiation

PhD student: Elena González Sánchez
Director/s: Juan Angel Recio Conde
University: Universitat Autònoma de Barcelona
Year: 2019

Study of the in vivo cooperation between oncogenic BRAF, LKB1 loss and UV irradiation

PhD student:
Director/s: Juan Angel Recio Conde
University: Universitat Autònoma de Barcelona
Year: 2019

Study of the in vivo cooperation between oncogenic BRAF, LKB1 loss and UV irradiation

PhD student: Elena González Sánchez
Director/s: Juan Angel Recio Conde
University: Universitat Autònoma de Barcelona
Year: 2019

Mecanismos epigenéticos con valor pronóstico en el carcinoma escamoso cutáneo

PhD student: Maria eugenia Hernandez Ruiz
Director/s: Vicente García-Patos Briones
University: Universitat Autònoma de Barcelona
Year: 2019

Caracterización de la expresión de ácido ribonucléico mensajero en distintos subtipos histológicos de carcinoma basocelular

PhD student: Patricia Bassas Freixas
Director/s: Vicente García-Patos Briones, Aleix Prat Aparicio
University: Universitat Autònoma de Barcelona
Year: 2018

Blog

News

On World Cancer Research Day, we highlight the impact of VHIR projects in the field of oncology.

The paper that analyzed to what degree the most commonly prescribed immunosuppressants increase the likelihood of melanoma was considered the best communication at the national congress of dermatology

Job offers

Predoctoral Position - BioMedical Research in Melanoma- Animal Models and Cancer Group
Start date:
14/06/2018
End date:
21/06/2018
Document: Download
Laboratory Technician Melanoma Biomedical
Start date:
18/09/2017
End date:
25/09/2017
Document: Download
Postdoctoral position
Start date:
18/03/2016
End date:
25/03/2016
Document: Download